OBJECTIVES: This study evaluated the sensitivity and specificity of a rapid, sensitive dot-immunoenzyme filtration assay to detect enterovirus 71 (EV71) antigen in serum samples from paediatric patients with hand, foot and mouth disease (HFMD), through detection of anti-EV71 immunoglobulin (Ig)M. METHODS: Serum samples from HFMD patients and healthy adult controls were evaluated for the presence of anti-EV71 IgM using a dot-immunoenzyme filtration assay (DIEFA). The results were compared with those obtained using a dotimmunogold filtration assay (DIGFA). The EV71 structural protein VP1 was used as the antigen for both assays. RESULTS: Serum samples from 72 HFMD patients and 54 healthy controls were evaluated. The DIGFA procedure showed a sensitivity of 98.5% and a specificity of 100%, whereas the DIEFA procedure showed a sensitivity of 98.6% and a specificity of 98.0%. There were no significant differences between the assays in either specificity or sensitivity. CONCLUSION: The DIEFA procedure developed in this study has potential as a rapid, simple, sensitive and cost-effective screening technique for detecting EV71 antigen in serum samples from patients with HFMD.
Introduction
Enterovirus 71 (EV71) is a major causative agent for hand, foot and mouth disease (HFMD) that has emerged as an important infectious disease among children in China. 1 There is no effective antiviral treatment for EV71; infection management depends on prompt diagnosis and timely implementation of appropriate measures to contain the spread of infection. 2 Laboratory diagnostic techniques include isolation of the virus in susceptible continuous cell lines and detection of viral RNA by polymerase chain reaction (PCR). 3, 4 Virus isolation remains the gold standard for enterovirus diagnosis and has been applied to the clinical diagnosis of HFMD. Enzymelinked immunosorbent assay (ELISA) has also been applied to the clinical diagnosis of HFMD, 2 but is not the gold standard for The present study reports the development of a dot-immunoenzyme filtration assay (DIEFA) for the detection of anti-EV71 immunoglobulin (Ig)M in serum samples. A dot-immunogold filtration assay (DIGFA) was used for direct comparison of the sensitivity and specificity of these assays. DIGFA is a rapid, simple and accurate assay that is being used increasingly in various fields of research, including for the detection of Schistosoma japonicum, 5,6 human cystic and alveolar echinococcosis, 7 insecticide carbaryl, 8 syphilis 9 and white-spot syndrome virus of shrimp. 10 To our knowledge DIEFA has not been reported previously.
Patients and methods

HUMAN SERUM SAMPLES AND ANTIBODY REAGENTS
Whole blood samples from paediatric patients with clinical features of HFMD and healthy controls (adult blood donors) were obtained from the Institute of Basic Medical Sciences, Beijing, China. The study protocol was approved by the Ethics Committee of the Chinese Ministry of Health. Written informed consent was obtained from the parents of the paediatric patients; verbal informed consent was obtained from the healthy controls.
The blood samples (2 ml) were allowed to clot by standing for 24 h at 4°C and were then centrifuged at 5000 rpm for 15 min (Sigma 1K15 centrifuge, Sigma-Aldrich, St Louis, MO, USA) to collect serum. The serum samples were stored at 4°C for < 4 weeks until use. All serum samples were coded by a data analyst and analysed by two different test teams using DIGFA and DIEFA, as described later in this paper.
The serum samples were diluted 1:20 in 0.5% Tween-20 in 0.01 M phosphatebuffered saline (PBS), pH 7.5. Colloidal gold labelled goat antihuman IgM (BioAassay Works, Ijamsville, MD, USA) was diluted 1:10 in 1% Tween-20 and 1% bovine serum albumin (BSA) in 0.01 M PBS, pH 7.5. Goat alkaline phosphatase-labelled polyclonal secondary antibody to the human IgM µchain (Abcam ® , Hong Kong, China) was diluted 1:500 in 1% Tween-20 and 0.5% BSA in 0.01 M PBS, pH 7.5. All diluted serum samples and secondary antibody solutions were stored at 4°C for up to 7 days until use.
EV71 ANTIGEN
The EV71 antigen selected for this protocol was the structural protein VP1, and was prepared as follows. Full-length EV71 cDNA (donated by The National Institute for the Control of Pharmaceutical and Biological Products, Beijing, China) was used as a template for the amplification of peptide coding regions. The protein sequence of EV71 was retrieved from the National Center for Biotechnology Information Entrez Protein Database (Bethesda, MD, USA).
The full-length EV71 cDNA was amplified by PCR using the MultiGene™ Mini Personal Thermal Cycler (Light Labs, Austin, TX, USA). The PCR reaction mix contained 1 × PCR buffer, 200 µM of each deoxynucleotide, 0.2 -1.0 µM of each primer, 2.5 U/100 µl of AmpliTaq ® polymerase and 0.05 -1.0 µg of template DNA. The primer sequences were: VP1 forward, 5′-GCGGATCCGGAGATAGGG TGGCAGAT-3′; VP1 reverse, 5′-GCGAAT TCAAGAGTGGTGATCGATGT-3′. The cycling programme involved preliminary denaturation at 95°C for 5 min, followed by 35 cycles of denaturation at 95°C for 30 s, annealing at 55°C for 30 s and elongation at 72°C for 60 s, with a final elongation step at 72°C for 15 min.
To produce an EV71 VP1-histidine tagged fusion protein, the EV71 VP1 PCR products were digested with the BamHI and EcoRI restriction enzymes for 3 h at 37°C, then ligated into the pET-28a expression vector (Novagen; EMD Millipore, Billerica, MA, USA), which contains a histidine tag. The ligation was carried out overnight (approximately 16 h) at 16°C using the T4 DNA ligase ligation system (New England Biolabs, Beijing, China) according to the protocol given in Fig. 1 . The EV71 VP1 expression plasmid was verified by sequencing analysis at the Chinese National Human Genome Centre, Beijing, China. The plasmid was then transfected into Escherichia coli for amplification and the histidinetagged recombinant proteins were purified using nickel-nitrilotriacetic acid (Ni-NTA) resin in a Ni-NTA purification system (Invitrogen™, Carlsbad, CA, USA). Concentrations of the purified VP1 proteins were determined using an ultraviolet spectrophotometer at a wavelength of 280 nm (Agilent 8453 UV-visible spectrophotometer; Agilent, Santa Clara, CA, USA).
DESIGN OF THE ASSAYS
An immunofiltration device to enable rapid reaction of antigen and antibody in situ was used for both assays and has been widely used. 9 -13 It comprised a rectangular plastic box (45 mm × 30 mm × 6 mm) with a test hole (diameter 10 mm) cut into the centre of the lid. The box was filled with waterabsorbing tissue paper and a nitrocellulose membrane (0.45 µm pore size; Waterman, Wendlingen, Germany) was positioned over the test hole. A 0.5-µl sample of human IgM (500 µg/ml) was applied to the upper surface to form a small dot over the test hole. Next to The DIEFA, developed in this study, used goat alkaline phosphatase-labelled polyclonal secondary antibody to the human IgM µchain; oxidation of the substrate 5-bromo-4chloro-3′-indolylphosphate p-toluidine salt (BCIP) in the presence of nitro-blue tetrazolium chloride (NBT) yields an intense, insoluble black-purple precipitate. 14 The DIGFA is a new solid-phase immunoassay that uses a nitrocellulose membrane as a support for the antigen and colloidal gold-labelled goat antihuman IgM secondary antibody; the immobilized colloidal gold particles appear as reddish dots. 11
DIGFA PROCEDURE
This assay was performed at room temperature without any specialist equipment. A 50-µl volume of diluted serum was dripped slowly onto the centre of the device test hole. After 1 min, the diluted serum was washed with five drops of washing solution (0.5% Tween-20 in 0.01 M PBS, pH 7.5). After washing, 50 µl of diluted colloidal gold-labelled goat antihuman IgM was added. The appearance of two reddish dots in the test hole opening indicated a positive reaction, whereas one reddish dot indicated a negative reaction (Fig. 2 ).
DIEFA PROCEDURE
This assay was performed under the same conditions as the DIGFA. A 50-µl volume of diluted serum was dripped slowly onto the centre of the device test hole. After 1 min, the diluted serum was washed with five drops of washing solution (0.5% Tween-20 in 0.01 M FIGURE 2: Dot-immunogold filtration assay for detection of enterovirus 71 (EV71). A nitrocellulose membrane was exposed first to human immunoglobulin (Ig)M (upper dot, control) or to EV71 VP1 protein (lower dot, test), then to serum samples from patients with hand, foot and mouth disease or healthy controls. IgM that remained attached was visualized using gold-labelled goat antihuman IgM. Immobilized colloidal gold particles appeared as reddish spots (shown here in grey).
(A) Positive test result (patient). (B) Negative test result (healthy control)
A B Dot-immunoenzyme filtration assay for detecting EV71 antigen PBS, pH 7.5) to remove the unbound conjugate. After washing, 50 µl of diluted goat alkaline phosphatase-labelled polyclonal secondary antibody to the human IgM µ-chain was added and allowed to soak in. After washing with washing solution, 50 µl of BCIP/NBT solution (33 µl of 50 mg/ml BCIP in 100% dimethylformamide and 16.5 µl of 50 mg/ml NBT in 70% dimethylformamide in 5 ml of buffer [100 mM Tris-HCl, pH 9.0, 150 mM saline, 1 mM magnesium chloride]; Promega, Shanghai, China) was added and the apparatus was placed in the dark for 2 min. The appearance of two blue dots in the test hole opening indicated a positive reaction, whereas one blue dot indicated a negative reaction (Fig. 3 ).
STATISTICAL ANALYSES
Data are presented as the number and percentage of patients with positive results for each test. Categorical data for the HFMD paediatric patient group and healthy adult controls were compared by the χ 2 -test using ZIYUE software, version 1.61 (available at: http://down.tech.sina.com.cn/content/29444. html). A P-value of < 0.05 was considered to be statistically significant.
Results
Serum samples were obtained from 72 patients with HFMD and 54 healthy controls. All patients were between 1 and 6 years of age; all healthy controls were ≥ 18 years of age.
For the DIGFA, only 65 patients with HFMD were tested due to a lack of serum samples from seven patients. The test results were positive in 64/65 (98.5%) of the patient samples; one sample gave a false-negative result ( Table 1) . Test results were negative in FIGURE 3: Dot-immunoenzyme filtration assay for detection of enterovirus 71 (EV71). A nitrocellulose membrane was exposed first to human immunoglobulin (Ig)M (upper dot, control) or to EV71 VP1 protein (lower dot, test), then to serum samples from patients with hand, foot and mouth disease or healthy controls. IgM that remained attached was visualized, using alkaline phosphatase-labelled polyclonal secondary antibody to the human IgM µ-chain, in the presence of 5-bromo-4-chloro-3′indolylphosphate p-toluidine salt and nitroblue tetrazolium chloride, which reacted to produce a black-purple spot (shown here in grey). For the DIEFA, only 50 healthy control samples were tested due to a lack of serum samples from four patients (Table 1) . Test results were positive in 71/72 (98.6%) of the patient samples; one sample gave an indeterminate result. The test result was positive for one (2.0%) of the 50 healthy control samples. A statistically significant difference in positive test results for the DIGFA and DIEFA tests was observed between patients and healthy controls (P < 0.01; Table 1 ).
Thus, the DIGFA test showed a sensitivity of 98.5% and a specificity of 100%, whereas the DIEFA test had a sensitivity of 98.6% and a specificity of 98.0%. There were no significant differences in either sensitivity or specificity between the two assays.
Discussion
Enterovirus 71 is a major causative agent for HFMD and is associated with various neurological diseases, such as aseptic meningitis, acute flaccid paralysis and fatal encephalitis. 15 To date, no effective antiviral treatment is available for this disease. Prompt diagnosis is very important in order to contain the spread of infection. 16, 17 It is usual for IgM antibodies to appear early during the course of an infection and then disappear, only to reappear (to a lesser extent) after further exposure. 18 The demonstration of anti-EV71 IgM in a serum sample indicates recent infection, and ELISA has been used to detect antibodies as part of the clinical diagnosis of HFMD. 2,19 -22 Traditional ELISA is, however, laborious and time-consuming to perform, and requires specialized equipment and trained personnel. DIGFA and DIEFA were used in the present study to detect of EV71 IgM by different labelling procedures. Both methods are simple enough to be performed by paramedical personnel without specialist training and provide a rapid (approximately 5 min per test) and convenient protocol for the detection of anti-EV71 IgM in serum.
Several studies have demonstrated the sensitivity of DIGFA to be lower than that for conventional ELISA procedures. 12, 13, 23 The present study showed DIGFA to have a sensitivity of 98.5% and a specificity of 100%, whereas DIEFA had a sensitivity of 98.6% and a specificity of 98.0%. There were no significant differences in specificity and sensitivity between the two assays. The specificity of ELISA has been reported to be 90 -100% for serum samples collected from EV71-infected patients at different time 2, 19 Each assay has potential advantages. For example, DIEFA employs a number of toxic reagents (such as BCIP and NBT) whereas DIGFA does not. DIEFA is, however, more economical than DIGFA, making its use potentially more attractive in developing countries. The price of 50 µl of diluted (1:10) colloidal gold-labelled goat antihuman IgM, used for DIGFA, was 7.5 RMB, whereas 50 µl of diluted (1:500) goat alkaline phosphataselabelled polyclonal secondary antibody to the human IgM µ-chain and 50 µl of NBT/BCIP, used for DIEFA, cost approximately 0.4 RMB.
In conclusion, both DIEFA and DIGFA offer test results that can be interpreted visually without any equipment, and both allow the reliable detection of anti-EV71 IgM from a small volume of serum. These tests may prove useful for the detection of EV71 and may find further large-scale applications in the detection of a variety of antibodies and antigens. The DIEFA procedure developed in this study has potential as a rapid, simple, sensitive and cost-effective screening technique for detecting EV71 antigen in serum samples from patients with HFMD.
